{
    "clinical_study": {
        "@rank": "25153", 
        "arm_group": [
            {
                "arm_group_label": "BTDS", 
                "arm_group_type": "Experimental", 
                "description": "Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr"
            }, 
            {
                "arm_group_label": "BTDS with naltrexone", 
                "arm_group_type": "Experimental", 
                "description": "Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets"
            }, 
            {
                "arm_group_label": "Naltrexone", 
                "arm_group_type": "Active Comparator", 
                "description": "Naltrexone 50 mg tablets"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Moxifloxacin 400-mg tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the ECG effects of 10, 40, and 80 mcg/hr\n      buprenorphine delivered by BTDS alone, or by BTDS dosed with naltrexone, relative to placebo\n      in healthy male and female subjects."
        }, 
        "brief_title": "The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (Mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "ECG Effects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide written informed consent.\n\n          -  Males and females aged 18 to 55, inclusive.\n\n          -  Body weight ranging from 50 to 100 kilograms (kg) (110 to 220 lbs) and body mass\n             index (BMI) ranging from 18 to 30 (kg/m2), inclusive.\n\n          -  Healthy and free of significant abnormal findings as determined by medical history,\n             physical examination, clinical laboratory values, vital signs, and resting 12-lead\n             ECG.\n\n          -  Females of child-bearing potential must be using an adequate and reliable method of\n             contraception (ie, barrier with additional spermicidal foam or jelly, intra-uterine\n             device, hormonal contraception). Females who are postmenopausal must have been\n             postmenopausal \u2265 1 year and have elevated serum follicle stimulating hormone (FSH).\n\n          -  Willing to eat the food supplied during the study.\n\n          -  Willing to refrain from strenuous exercise during the entire study. Subjects will not\n             begin a new exercise program nor participate in any unusually strenuous physical\n             exertion.\n\n          -  All 8 anatomical transdermal system (TDS) application sites (upper back, upper chest,\n             upper outer arm, or lateral thorax) must be acceptable for study use.\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant (positive beta human chorionic gonadotropin test) or\n             lactating.\n\n          -  Current or recent (within 5 years) history of drug or alcohol abuse.\n\n          -  History or any current conditions that might interfere with drug absorption\n             (transdermal or gastrointestinal), distribution, metabolism or excretion.\n\n          -  Use of an opioid-containing medication in the past 30 days preceding the initial dose\n             in this study.\n\n          -  Known allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or\n             hypnotic drugs, and/or moxifloxacin or any member of the quinolone class drugs.\n\n          -  Any history of frequent nausea or emesis regardless of etiology.\n\n          -  Any history of seizures or head trauma with sequelae.\n\n          -  Participation in a clinical drug study during the 30 days preceding the initial dose\n             in this study.\n\n          -  Any significant illness during the 30 days preceding the initial dose in this study.\n\n          -  Use of any medication including thyroid hormonal therapy (hormonal contraception and\n             hormonal replacement therapy in the form of estrogen with or without progestin is\n             allowed), vitamins, herbal and/or mineral supplements during the 7 days preceding the\n             initial dose.\n\n          -  Any personal or family history of prolonged QT interval or disorders of cardiac\n             rhythm.\n\n          -  Abnormal cardiac conditions including hypertension.\n\n          -  Abnormal cardiac condition denoted by any of the following:\n\n               -  QTcF interval > 450 milliseconds (msec)\n\n               -  PR interval > 240 msec or QRS > 110 msec\n\n               -  Evidence of second- or third-degree atrioventricular (AV) block\n\n               -  Pathological Q-waves (defined as Q-wave >40 msec or depth > 0.5 mV)\n\n               -  Evidence of ventricular pre-excitation, complete left bundle branch block, right\n                  bundle branch block (RBBB), or incomplete RBBB\n\n               -  With a resting heart rate outside the range of 45 to 85 beats per minute (bpm)\n\n          -  Abnormalities on physical examination, vital signs, ECG, or clinical laboratory\n             values, unless those abnormalities were judged clinically insignificant by the\n             investigator.\n\n          -  Oxygen saturation (SpO2) \u2264 94% as measured by pulse oximetry.\n\n          -  Refusal to abstain from caffeine or xanthine containing beverages entirely during\n             confinement.\n\n          -  Refusal to abstain from consumption of alcoholic beverages 48 hours prior to initial\n             study drug administration and any time during study.\n\n          -  History of smoking or use of nicotine products within 45 days of study drug\n             administration or a positive urine cotinine test\n\n          -  Blood or blood products donated within 30 days prior to study drug administration or\n             anytime during the study.\n\n          -  Positive results of urine drug screen or alcohol screen.\n\n          -  Positive results of hepatitis B surface antigen (HBsAg), hepatitis C antibody\n             (anti-HCV).\n\n          -  Positive naloxone challenge test.\n\n          -  Presence of Gilbert's Syndrome, or any known hepatobiliary abnormalities.\n\n          -  The investigator believes the subject to be unsuitable for reason(s) not specifically\n             stated in the exclusion criteria.\n\n          -  Subjects who have allergies or other contraindications to transdermal systems or\n             patch adhesives.\n\n          -  Clinically significant history of allergic reaction to wound dressings or\n             elastoplast.\n\n          -  Subjects with a dermatological disorder at any relevant patch application site that\n             precludes proper placement and/or rotation of patch.\n\n          -  Taking antihistamines within 72 hours prior to dosing or systemic or topical\n             corticosteroids within 3 weeks prior to dosing.\n\n          -  Subjects will not allow hair to be removed at the proposed patch application site\n             which may prevent proper placement of the patch.\n\n          -  Subjects for whom a proper assessment of possible application site reactions would be\n             confounded by local skin conditions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "328", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999114", 
            "org_study_id": "BUP1025"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BTDS", 
                    "BTDS with naltrexone"
                ], 
                "description": "Buprenorphine transdermal patch applied transdermally for 7-day wear", 
                "intervention_name": "Buprenorphine transdermal patch", 
                "intervention_type": "Drug", 
                "other_name": "Butrans"
            }, 
            {
                "arm_group_label": [
                    "BTDS with naltrexone", 
                    "Naltrexone"
                ], 
                "description": "Naltrexone tablet; 1 tablet taken orally every 12 hours", 
                "intervention_name": "Naltrexone tablet", 
                "intervention_type": "Drug", 
                "other_name": "ReVia"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebos", 
                "intervention_name": "Placebos (for TDS and for naltrexone and for moxifloxacin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "description": "Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17", 
                "intervention_name": "Moxifloxacin tablet", 
                "intervention_type": "Drug", 
                "other_name": "Avelox\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Naltrexone", 
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy subjects", 
            "Opioid", 
            "Transdermal", 
            "ECG"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }, 
                "name": "PPD Phase I Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 Mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The ECG effects of 10 mcg/hr buprenorphine (Day 6) delivered by BTDS alone, or by BTDS dosed with naltrexone relative to placebo.", 
                "measure": "Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (\u0394\u0394QTcI)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 6"
            }, 
            {
                "description": "The ECG effects of 40 mcg/hr buprenorphine (Day 13) delivered by BTDS alone, or by BTDS dosed with naltrexone relative to placebo.", 
                "measure": "Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (\u0394\u0394QTcI)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 13"
            }, 
            {
                "description": "The ECG effects of 80 mcg/hr buprenorphine (Day 17) delivered by BTDS alone, or by BTDS dosed with naltrexone relative to placebo.", 
                "measure": "Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (\u0394\u0394QTcI)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 17"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "QTcF and QTcB for historical purposes,  heart rate (HR), PR interval, QRS interval, uncorrected QT interval, ECG morphology", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 6, Day 13, and Day 17"
            }, 
            {
                "description": "The relationship between the placebo-corrected (placebo-adjusted) change from baseline in QTc intervals (QTcI, QTcF and QTcB) and plasma concentrations of buprenorphine and its metabolite, norbuprenorphine, with and without naltrexone.", 
                "measure": "Correlation between the QTcI change from baseline and maximum observed plasma concentrations (Cmax) of buprenorphine and norbuprenorphine", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to end of study"
            }
        ], 
        "source": "Purdue Pharma LP", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Purdue Pharma LP", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}